Suave Med Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-06-2024
- Paid Up Capital ₹ 0.20 M
as on 23-06-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 Cr
as on 23-06-2024
- Revenue %
(FY 2022)
- Profit -539.40%
(FY 2022)
- Ebitda -3748.32%
(FY 2022)
- Net Worth -1244.26%
(FY 2022)
- Total Assets 2731.60%
(FY 2022)
About Suave Med Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹4.00 Cr.
Sulabh Nayyar, Saksham Sabharwal, and Sidhaant Sabharwal serve as directors at the Company.
- CIN/LLPIN
U52190HR2020PTC085482
- Company No.
085482
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurgaon, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Suave Med Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sulabh Nayyar  | Director | 21-Jan-2021 | Current |
| Saksham Sabharwal | Director | 19-Feb-2020 | Current |
| Sidhaant Sabharwal | Director | 19-Feb-2020 | Current |
Financial Performance of Suave Med Sciences.
Suave Med Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 539.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1244.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suave Med Sciences?
In 2021, Suave Med Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sidhaant Life Sciences Private LimitedActive 20 years 2 monthsSulabh Nayyar and Sidhaant Sabharwal are mutual person
Synthesis Marketing Ventures Private LimitedActive 4 years 11 monthsSaksham Sabharwal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Dec 2022 | ₹4.00 Cr | Open |
How Many Employees Work at Suave Med Sciences?
Unlock and access historical data on people associated with Suave Med Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suave Med Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suave Med Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
